{"id":"NCT02207725","sponsor":"Portola Pharmaceuticals","briefTitle":"A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Apixaban Anticoagulation With Intravenously Administered Andexanet Alfa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2015-04","completion":"2015-09","firstPosted":"2014-08-04","resultsPosted":"2018-09-27","lastUpdate":"2023-08-08"},"enrollment":68,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bleeding"],"interventions":[{"type":"BIOLOGICAL","name":"Andexanet","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Andexanet","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.","primaryOutcome":{"measure":"Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)","timeFrame":"Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)","effectByArm":[{"arm":"Placebo (Part I)","deltaMin":-20.71,"sd":8.559},{"arm":"Andexanet (Part I)","deltaMin":-93.86,"sd":1.65},{"arm":"Placebo (Part II)","deltaMin":-32.7,"sd":5.578},{"arm":"Andexanet (Part II)","deltaMin":-92.34,"sd":2.809}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["26559317"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Infusion Related Reaction","Vessel Puncture Site Haemorrhage","Dermatitis Contact","Headache","Vessel Puncture Site Pain"]}}